Ophthalmology Approved Deal Benchmarks (2026)
Median upfront of $3.5B with total deal values reaching $9.2B.
Median Upfront
$3.5B
Total Deal Value
$8.0B
Royalty Range
17.9%–30%
Territory Multiplier
1x
Understanding Ophthalmology Deal Benchmarks at Approved
Approved Ophthalmology licensing deals command a median upfront payment of $3.5B, with values ranging from $2.6B at the low end to $4.2B for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the ophthalmology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $6.8B to $9.2B, with a median of $8.0B. Royalty rates for ophthalmology assets at this stage typically fall between 17.9% and 30% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $2.6B | $3.5B | $4.2B |
| Total Deal Value | $6.8B | $8.0B | $9.2B |
| Royalty Rate | 17.9% | — | 30% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Iveric Bio | Astellas Pharma | $5.9B | $5.9B | acquisition |
| 2022 | Aerie Pharmaceuticals | Alcon | $770M | $770M | acquisition |
| 2023 | Apellis Pharmaceuticals | N/A (standalone) | $0M | $7.0B | licensing |
| 2023 | Aldeyra Therapeutics | N/A (standalone) | $0M | $500M | licensing |
| 2024 | OcuTerra Therapeutics | N/A (standalone) | $0M | $100M | licensing |
| 2023 | Clearside Biomedical | Arctus Therapeutics | $20M | $250M | licensing |
| 2024 | Outlook Therapeutics | N/A (standalone) | $0M | $200M | licensing |
| 2023 | Ocuphire Pharma | Viatris | $30M | $400M | licensing |
| 2024 | REGENXBIO | AbbVie | $370M | $1.6B | licensing |
| 2024 | Roche/Genentech | N/A (standalone) | $0M | $5.2B | licensing |
See All Comparable Deals
View 10 comparable Ophthalmology transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Approved Ophthalmology deals?
How does Global territory affect Ophthalmology deal value?
What royalty rates are typical for Approved Ophthalmology licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$58M upfront
Ophthalmology · Preclinical · Global
$158M upfront
Ophthalmology · Phase 1 · Global
$496M upfront
Ophthalmology · Phase 2 · Global
$1.4B upfront
Ophthalmology · Phase 3 · Global
$2.1B upfront
Oncology · Approved · Global
$1.5B upfront
Neurology/CNS · Approved · Global
$3.4B upfront
Immunology · Approved · Global
$3.5B upfront
Metabolic/Obesity · Approved · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Ophthalmology Approved Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/ophthalmology-approved-deals-global
<a href="https://solidus.ambrosiaventures.co/data/ophthalmology-approved-deals-global">Ophthalmology Approved Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=ophthalmology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.